LLY241206C700000
- 110.70
- +12.61+12.86%
Eli Lilly and Co Newsroom
Jim Cramer: This Energy Stock Is A 'Winner,' But Navitas Semiconductor Is 'Losing A Lot Of Money'
Update: Eli Lilly Says Its Zepbound Showed 47% 'Greater Relative Weight Loss' Against Wegovy in Phase 3b Trial
Express News | Rondo Therapeutics Announces Collaboration With Lilly to Develop Novel Cd28 Bispecific Antibodies for Solid Tumors
US Morning News Call | Stock Index Futures Climb on Positive Earnings, Focus Shifts to Upcoming Speech by Powell
Eli Lilly (LLY.US) outperformed Novo Nordisk (NVO.US) in the comparative trial showing that Zepbound is superior to Wegovy.
Eli Lilly and Co (LLY.US) announced that its weight loss drug Zepbound performed better in the first head-to-head trial compared to the competitor novo-nordisk a/s (NVO.US) Wegovy.
Eli Lilly and Company's (NYSE:LLY) Intrinsic Value Is Potentially 64% Above Its Share Price
Eli Lilly's Zepbound Beats Novo Nordisk's Wegovy in First Head-to-Head Study
Express News | Eli Lilly Shares up 1.3% Premarket After Co's Weight-Loss Drug Tops Rival Wegovy in Head-to-Head Study
Express News | Eli Lilly Announced Topline Results From The SURMOUNT-5 Phase 3b Open-label Randomized Clinical Trial
Express News | Lilly: At 72 Weeks, Zepbound Beat Wegovy on Both Primary Endpoint, All Five Key Secondary Endpoints in Trial
Express News | Lilly's Zepbound (Tirzepatide) Superior to Wegovy (Semaglutide) in Head-to-Head Trial Showing an Average Weight Loss of 20.2% Vs. 13.7%
Express News | Lilly: In Phase 3B Trial, Zepbound Provided a 47% Greater Relative Weight Loss Vs Wegovy
Express News | Lilly: In Phase 3B Trial, Participants Using Zepbound Lost 50.3 Lbs. (22.8 Kg) and Participants on Wegovy Lost 33.1 Lbs. (15.0 Kg)
Express News | Lilly: Commonly Reported Adverse Events in Surmount-5 for Zepbound & Wegovy Were Gastrointestinal-Related, Generally Mild to Moderate in Severity
Lilly's Zepbound (Tirzepatide) Superior to Wegovy (Semaglutide) in Head-to-head Trial Showing an Average Weight Loss of 20.2% Vs. 13.7%
Fresh Closing Highs from S&P 500 and Nasdaq | Wall Street Today
BeiGene Started at Overweight at Morgan Stanley on Brukinsa Market Share Growth
Express News | 'ADA Advises Against Using Compounded GLP-1 RA Medications' - Medscape
Tuesday S&P 500 Pulls Back From Highs, Nasdaq Climbs | Live Stock
Sector Update: Health Care Stocks Decline Premarket Tuesday